Indolent Non-Hodgkin Lymphoma — Trials

Indolent Non-Hodgkin Lymphoma — Trials · CancerIndex

Clinical trials

Registered studies

791 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 212
Recruiting: 103
Ph III recruiting: 4
Growth YoY: +51.7%
Industry share: 20%
Top sponsor: City of Hope Medical Center
Termination share: 36.9%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (150)

clinicaltrialsPublishedShowing 1–4 of 4 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT01804686	A Long-term Extension Study of PCI-32765 (Ibrutinib)(CAN3001)	recruiting	Phase 3	700	Janssen Research & Development, LLCINDUSTRY	30	Jul 31, 2026	clinicaltrials
NCT06006117	Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma	recruiting	Phase 3	260	The Lymphoma Academic Research OrganisationOTHER	5	Jun 15, 2026